FDA appeal win for wet AMD opens a clear US approval path.
OTLK's FDA appeal win for Litenav in wet AMD creates a credible US-approval pathway, making the setup strongly bullish after the stock re-rated sharply.
FDA granted Outlook Therapeutics' appeal and found substantial evidence of effectiveness for Litenav in treating wet AMD. The agency directed final labeling work and Outlook expects to resubmit a biologics license application in June 2026, with review timing that can accelerate an approval decision.
6mo
"🔥Buy Every Share You Can (Do Not Wait‼️)"